Gut

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER


[Advanced]
Gut 2006;55:1217
Copyright © 2006 BMJ Publishing Group Ltd & British Society of Gastroenterology
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Spiller, R.
Right arrow Articles by Watson, A.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Spiller, R.
Right arrow Articles by Watson, A.
Topic Collections
Right arrowRelevant Articles

Digest

Robin Spiller, Editor, Alastair Watson, Deputy Editor

The first 150 words of the full text of this article appear below.


ABLATION OF BARRETT’S OESOPHAGUS: THE GOOD AND BAD NEWS
With the rising incidence of adenocarcinoma of the oesophagus, a method of eliminating Barrett’s oesophagus would be a step forward. The authors randomised 35 patients with Barrett’s oesophagus to ablative treatment with either multipolar electrocoagulation or argon beam coagulation. The good news is that both treatments eliminated Barrett’s oesophagus at 2 years in approximately 70% of patients, with neither treatment showing any statistical advantage over the other. Adverse events and outcomes were rare. Unfortunately it was not possible to identify risk factors for treatment failure. The bad news is that ablative treatment does not eliminate the need for surveillance as ablation is incomplete in 30% of patients. Repeated biopsies are required of the previous Barrett’s area to identify these treatment failures. Furthermore, it is still unknown whether such ablative treatment reduces the risk of subsequent adenocarcinoma. The authors conclude ablative treatment is not yet ready for clinical practice except as . . . [Full text of this article]


Relevant Articles

A randomised controlled trial of ablation of Barrett’s oesophagus with multipolar electrocoagulation versus argon plasma coagulation in combination with acid suppression: long term results
P Sharma, S Wani, A P Weston, A Bansal, M Hall, S Mathur, A Prasad, and R E Sampliner
Gut 2006 55: 1233-1239. [Abstract] [Full Text] [PDF]

Cost effectiveness of interferon {alpha} or peginterferon {alpha} with ribavirin for histologically mild chronic hepatitis C
R Grieve, J Roberts, M Wright, M Sweeting, D DeAngelis, W Rosenberg, M Bassendine, J Main, and H Thomas
Gut 2006 55: 1332-1338. [Abstract] [Full Text] [PDF]

The gut–joint axis: cross reactive food antibodies in rheumatoid arthritis
M Hvatum, L Kanerud, R Hällgren, and P Brandtzaeg
Gut 2006 55: 1240-1247. [Abstract] [Full Text] [PDF]

Hepatic stellate cells express synemin, a protein bridging intermediate filaments to focal adhesions
N Uyama, L Zhao, E Van Rossen, Y Hirako, H Reynaert, D H Adams, Z Xue, Z Li, R Robson, M Pekny, and A Geerts
Gut 2006 55: 1276-1289. [Abstract] [Full Text] [PDF]

Survival and cause specific mortality in patients with inflammatory bowel disease: a long term outcome study in Olmsted County, Minnesota, 1940–2004
T Jess, E V Loftus, Jr, W S Harmsen, A R Zinsmeister, W J Tremaine, L J Melton, III, P Munkholm, and W J Sandborn
Gut 2006 55: 1248-1254. [Abstract] [Full Text] [PDF]

Insulin-like growth factor I improves intestinal barrier function in cirrhotic rats
V Lorenzo-Zúñiga, C M Rodríguez-Ortigosa, R Bartolí, M-L Martínez-Chantar, L Martínez-Peralta, A Pardo, I Ojanguren, J Quiroga, R Planas, and J Prieto
Gut 2006 55: 1306-1312. [Abstract] [Full Text] [PDF]





HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
Terms and conditions relating to subscriptions purchased online  ¦  Website terms and conditions  ¦  Privacy policy
Copyright © 2006 BMJ Publishing Group Ltd & British Society of Gastroenterology